| Species |
Human |
| Protein Construction |
RGMa (Cys48-Gly422)
Accession # Q96B86-1 |
His |
Avi |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized RGMa[Biotin], His & Avi, Human at 1μg/ml (100μl/Well) on streptavidin (5μg/ml) precoated plate can bind Human Neogenin, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
44.5 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 45-48 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Repulsive guidance molecule (RGM) is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein that has diverse functions in the developing and pathological central nervous system (CNS). The binding of RGM to its receptor neogenin regulates axon guidance, neuronal differentiation, and survival during the development of the CNS. RGMa induces T cell activation in experimental autoimmune encephalomyelitis (EAE), which is the animal model of multiple sclerosis (MS). |
| Synonyms |
RGMA; RGM |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
